Indaptus Therapeutics, Inc.INDPNASDAQ
Loading
Free Cash Flow Growth Recovery in ProgressRecovering
Percentile Rank71
5Y CAGR-86.6%
Year-over-Year Change
Year-over-year free cash flow growth rate
5Y CAGR
-86.6%/yr
Long-term compound
Percentile
P71
Within normal range
vs 5Y Ago
0x
Contraction
Streak
2 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q3 2025 | 23.98% |
| Q2 2025 | 20.39% |
| Q1 2025 | -48.63% |
| Q4 2024 | -35.13% |
| Q3 2024 | -1.42% |
| Q2 2024 | 37.05% |
| Q1 2024 | -51.29% |
| Q4 2023 | 30.32% |
| Q3 2023 | -77.26% |
| Q2 2023 | 57.54% |
| Q1 2023 | -124.04% |
| Q4 2022 | 66.13% |
| Q3 2022 | -107.72% |
| Q2 2022 | -0.98% |
| Q1 2022 | 11.92% |
| Q4 2021 | 37.15% |
| Q3 2021 | -334.27% |
| Q2 2021 | -57.09% |
| Q1 2021 | 13.73% |
| Q4 2020 | -121.49% |
| Q3 2020 | 545334.59% |
| Q2 2020 | -97.85% |
| Q1 2020 | 99.99% |
| Q4 2019 | 26.67% |
| Q3 2019 | 32.39% |
| Q2 2019 | -47.50% |
| Q1 2019 | 24.36% |
| Q4 2018 | 10.48% |
| Q3 2018 | -9.26% |
| Q2 2018 | 19.94% |
| Q1 2018 | -26.23% |
| Q4 2017 | -34.28% |
| Q3 2017 | 0.00% |
| Q2 2017 | 0.00% |
| Q1 2017 | 0.00% |
| Q4 2015 | -1587.11% |
| Q3 2015 | 85.37% |
| Q2 2015 | 0.00% |
| Q1 2015 | 0.00% |